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ABSTRACT
A 45-year-old patient presented with a
cerebrovascular attack and was subsequently
found to have a multi-fenestrated atrial septal
defect. Various therapeutic options for
percutaneous transcatheter closure with their
respective benefits and flaws are discussed, as
well as procedural and financial considerations.
The decision making process leading to a
successful result using a single occlusive device
is presented, alongside a review of the literature.
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INTRODUCTION
Atrial septal defects (ASDs) account for 10–17%
of congenital cardiac anomalies [1].
Percutaneous closure of ostium secundum ASD
is a safe and effective alternative to surgery [2].
Nearly 10% of patients with secundum-type
ASD are found to have multi-fenestrated ASDs
(mfASDs) [3]. The closure of more than one
defect poses several challenges to the
cardiologist. The authors describe a case of a
woman with multiple ASDs who was
successfully treated with a single ASD occluder.
CASE REPORT
The patient was a 45-year-old female who had a
cerebrovascular attack (CVA), presenting with
dysarthria and right hemiparesis. Computed
tomography of the brain was interpreted as
normal on the second day of symptoms. The
patient’s neurologic symptoms gradually
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improved and the patient resumed her work as a
school teacher 3 months following the acute
event.
There was no history of smoking, the
patient’s blood pressure was normal, and
blood tests for renal and liver functions were
normal. Fasting blood glucose and cholesterol
were within the normal limits. The patient
underwent a Doppler study of carotid and
vertebrobasilary arteries, which were found to
be normal. Hypercoagulability workup was also
normal.
The patient did not report palpitations. The
patient’s parents were treated for arterial
hypertension. A 24-h electrocardiogram Holter
study was normal, with no paroxysmal atrial
fibrillation events and no other ectopic activity.
During a routine transthoracic
echocardiogram (TTE) study, the right
ventricle was noted to be mildly dilated and a
small-to-moderate, left-to-right flow was
observed across a fenestrated interatrial
septum (IAS). There was normal biventricular
function with no hypertrophy. Very mild,
nonrheumatic mitral valve regurgitation was
observed and minimal physiologic
regurgitation of the tricuspid valve was noted
with a systolic continuous wave Doppler
gradient of 22 mmHg, resulting in a normal
estimate of pulmonary artery pressure.
After informed consent was obtained, the
patient underwent general anesthesia with
endotracheal intubation. A transesophageal
echocardiogram (TEE), performed in the
catheterization laboratory for the guidance of
transcatheter closure of the defect, revealed a
floppy IAS with four fenestrations (Fig. 1).
Agitated saline injection through the right
femoral vein with simulation of Valsalva
maneuver by the anesthesiologist induced a
large amount of microbubbles shunting right-
to-left across the IAS. A decision was made to
close the defects using a single device. The
authors used the Occlutech Figula Flex ASD
15 mm (H. ? H. Maslanka GmbH, Stockacker,
Germany) occluder for this fenestrated IAS. The
author sized and deployed the device in one of
the central defects, which measured 15 mm.
A leak still existed outside the perimeter of the
device (Fig. 2). A second attempt was
subsequently performed in the adjacent
central defect, using the Occlutech Figula
Fig. 1 A transesophageal echocardiogram demonstrating a
multifenestrated atrial septal defect with four openings
(arrows)
Fig. 2 A transesophageal echocardiogram demonstrating a
deployed occluding device in one of the atrial septal
defects. There is a leak outside the perimeter of the device
(arrow). LA left atrium, RA right atrium
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Flex ASD 21 mm (H. ? H. Maslanka GmbH,
Stockacker, Germany) occluder. Residual leak
was demonstrated only within the perimeter of
the device (Fig. 3). At that stage the device was
released. The adequacy of device position was
confirmed by gentle tagging of the deployed
device prior to release and by TEE imaging. The
procedure was uneventful and lasted 65 min,
most of which was dedicated to thorough TEE
investigation and planning. The screening time
was 18 min.
During the procedure, the patient was given
6,000 units of heparin and 1,000 mg of
cefazoline intravenously, followed by two
additional cefazoline doses over 24 h.
Following the procedure, the patient was
started on clopidogrel 75 mg/day for 3 months
and aspirin 100 mg/day for 1 year to allow
complete endothelialization of the occlusive
device.
On a follow-up visit 1 month after the
procedure, the device was found to be
properly placed without any IAS leaks,
confirmed via TEE. There was no interference
with cardiac inflows and no impingement on
heart valves. Currently, 6 months after the
procedure, the patient is asymptomatic with
no additional neurological events, and is
leading a normal life.
DISCUSSION
Children and adults with secundum-type ASD
may present with mfASDs. Clinical indications
for closure of the defects are as for a single ASD,
including symptomatic patients and/or
increased pulmonary blood flow [pulmonary-
to-systemic flow ratio (Qp:Qs) [1.5:1]. While
surgery was the only available treatment for
secundum ASD in the past, nowadays
the preferable therapeutic modality is by the
percutaneous approach. Although the
transcatheter approach becomes the treatment
of choice for ASD patients, surgical results
remain the gold standard [4]. Surgery
continues to be indicated for patients who
prefer to avoid implantation of a foreign body,
for defects that are too large to be closed by an
implantable device or lack adequate rim for a
device to lean on, and for unfavorable IAS
morphology precluding successful and safe
closure of the defects using one or several
occlusive devices. In elderly patients, the
prompt recovery following transcatheter ASD
closure makes this alternative approach to
surgery more attractive in view of prolonged
convalescence and an increased rate of
significant complications in the older
population due to comorbidities [4].
Since the first reported transcatheter closure
of secundum ASD by King et al. in 1976 [5], its
use has been widely accepted as a highly
effective and safe alternative to surgery [5].
The percutaneous transcatheter closure of
fenestrated ASDs may be more complicated
than closure of a single ASD, and requires
Fig. 3 A transesophageal echocardiogram demonstrating a
deployed occluding device in one of the atrial septal
defects. Residual shunt is present within the perimeter of
the device (arrow)
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careful investigation of the anatomy of the
defects and their surroundings, as well as
prudent selection of the most appropriate
method. The transcatheter closure of a
multiple or fenestrated ASD can be
accomplished by several methods.
The defects may be closed by the use of
several devices, each of the devices implanted to
close one or more defects. When the distance
between the ASDs is greater than 7 mm,
placement of two devices may be
recommended [6]. Awad et al. [6] published a
series of 33 patients who underwent multiple
ASD closure using more than one device, with a
97% immediate success rate. There were two
cases of complications. The first was device
embolization and the second was device erosion
due to oversizing of a device. The second case
needed a surgical removal of the devices. The
explanted devices showed complete
endothelialization, refuting previous findings
of noncovering due to devices overlap [7].
Closure of the larger defect should be
performed first [6, 8]. The second device may
have to be larger in order to overlap the rim of
the first device, in spite of the smaller stretched
diameter of the defect. The cardiologist may
mistake a star-shaped defect for multiple small
defects. This might cause the first smaller device
to be easily pulled through upon deployment.
Awad et al. used the Amplatzer septal
occluder (AGA Medical Corporation,
Plymouth, MN, USA) for all but one (who
received two Amplatzer Cribriform [AGA
Medical Corporation, Plymouth, MN, USA]
devices) of their series [6]. Other investigators
have used Amplatzer PFO occluders (AGA
Medical Corporation, Plymouth, MN, USA),
CardioSEAL and STARflex occluders (NMT
Medical Inc., Boston, MA, USA), and GORE
HELEX septal occluders (W. L. Gore &
Associates, Elkton, MD, USA) [8].
When using more than one device, attention
should be paid to adequate distance from
structures like the vena cavae entrances and
the coronary sinus. The devices might interfere
with blood flow and even increase the risk for
thrombosis. This, however, has not been
apparent in follow-up studies, even after
cessation of antiplatelets therapy [9]. In
addition, the devices might cause erosion of
important tissues, including the aortic root, the
atrioventricular valves, or the atrial free walls.
Nevertheless, closure of multiple ASDs using
multiple occluders seems to be a safe and
effective method.
An additional financial issue that should be
considered when implanting more than one
device is the reimbursement system used by
current health maintenance organizations
(HMOs). Since the cost of percutaneous closure
of ASD is reimbursed according to a specific
diagnosis-related group (DRG), closing multiple
ASDs using more than one device during a single
procedure will exceed the DRG budget.
When multiple ASDs cannot be closed with
one large device or two to three smaller devices,
performing an atrial balloon septostomy
followed by device closure of the single
iatrogenic ASD has been proposed [10]. While
it has been successfully accomplished
previously, this method carries the risk of
creating an unpredictable, irregular, large hole.
Such a hole might not be readily closed
percutaneously.
When the defects are in close proximity, an
attempt may be made to close them all using a
single device. Szkutnik et al. [11] reported its
feasibility in 2004. A distance of less than 7 mm
between the defects is considered appropriate
for this procedure. A larger device should be
employed in order to cover all the defects.
However, it was suggested that even if residual
leaks were observed they tend to resolve with
100 Cardiol Ther (2013) 2:97–102
123
time [11]. In addition to the diameter of the
device to be used, a decision has to be made
regarding the type of device. A single regular
ASD occluder inserted through the central or
largest defect will be stabilized in place by its
waist. The waist will also stretch the IAS; thus,
bringing the surrounding defects in proximity
and decreasing their size.
A fenestrated ASD is often associated with
atrial septal aneurysm. Some cardiologists prefer
to close these lesions using Cribriform devices [9,
12]. These are characterized by large discs and a
narrow waist (or connecting pin). This structure
means that thedevicedoesnot relyontheflexible
septum to stabilize its position but rather uses its
larger discs to stabilize the aneurysmal septum.
Straightening the aneurysmal septum may also
decrease the size of the defects. The size of the
device is determined by the ‘‘steady rim,’’ which is
the area that should include all defects [12].
Nevertheless, using a device which has an
interconnecting pin rather than the regular
waist means that after the release the device
may cruise around the hole into which it was
released, if the discs are not adherent to the IAS.
Therefore, the final position may vary and should
be re-inspected to ensure a proper defects closure.
The benefits of using a single device are a
shorter procedure duration and lesser chance of
interference with venous blood flow,
atrioventricular valves function, or adjacent
tissue erosion. However, an oversized device
on a floppy IAS might cause tissue dissection or
arrhythmogenicity. In the authors’ experience
of 541 ASD closures, 13% of which were
fenestrated, only one case needed two devices
for closure (unpublished data).
From the authors’ experience, it is possible
and advantageous to use a single device for
mfASD closure. In comparison with the recently
published data of the H. Sievert group [13], who
reported 35.8% of patients with mfASD who
were treated with more than one device, the
authors’ group implanted two devices in a
single patient, which accounts for only 0.2%
(unpublished data). The report staged procedure
in 49 of the 53 patients who required multiple
devices, which meant separate interventions for
most patients who received more than one
device [13]. The only patient that the authors
treated with two devices had them implanted
during one procedure. These data reflect a
difference in the clinical approach rather than
diversity in technical/procedural experience.
The present patient experienced a CVA at a
relatively young age. A thorough investigation
did not disclose any apparent etiology for this
event other than a cryptogenic stroke due to a
paradoxical embolus through the mfASD.
Although the patient’s interatrial shunt was left-
to-right, events such as Valsalva maneuver and
cough maytransiently reverse theflow, leading to
paradoxical emboli and CVA. Furthermore, these
defects caused right ventricular enlargement with
pulmonary overflow. These findings and the
patient’s CVA history were indicative for ASD
closure. The expected benefits for the present
patient included prevention of a recurrent stroke
due to a presumed paradoxical emboli and
prevention of further cardiac complications
including arrhythmia, heart failure, and
deteriorating functional capacity. There was also
a risk (though relatively low) for increasing
pulmonary vascular resistance without ASD
closure.
After an informed consent was obtained
from the patient, a TEE was performed in the
cardiac catheterization laboratory. It
demonstrated a floppy IAS and a mfASD with
four openings in close proximity. The exact
distance between the defects could not be
measured as they were in different anatomical
planes. The authors decided to close the mfASD
using a single device.
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CONCLUSION
The authors described the management of a
patient with multiple ASDs, discussed the
different therapeutic options for percutaneous
transcatheter closure with their respective
benefits and flaws, and described the decision-
making process leading to the successful result.
Future trials should compare the complications
and success rate of mfASD closure using a single
device versus multiple devices, and single versus
staged procedures. It should be considered
whether a surgical approach may be preferable
in complex cases of mfASDs requiring multiple
devices.
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